"After listening to Biodel's last conference call again I have come to the following conclusions:
"It appears to me that Biodel expects the FDA to require additional trials. If that is the case then I think that pushes the approval date into May of 2011. Biodel's management has also stated they want to launch with the "pen injector" for which Biodel must submit supplemental data."
"Biodel will need additional pipe funding before then."
"I'm thinking the share price bottoms in the $2.85 range next April."